Anemia in Chronic Kidney Disease
ICER will assess the comparative clinical effectiveness and value of roxadustat (AstraZeneca) for treatment of anemia in chronic kidney disease (CKD). Roxadustat is currently undergoing FDA review, with an anticipated decision expected at the end of this year.
Date of Review: February 2021
For questions or additional information, please contact Laura Cianciolo, Program Manager, at email@example.com.
The CTAF will convene to deliberate and vote on evidence presented in ICER's report on therapies for anemia in chronic kidney disease (CKD).